AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 251 min read$RGEN

Loeillot Olivier sold $2.5M of RGEN

Loeillot Olivier (Chief Executive Officer) sold 12,946 shares of REPLIGEN CORP (RGEN) at $190.00 ($2.46M total) across 2 trades on 2026-09-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Loeillot Olivier
Published Sep 25, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RGEN
Bearish
high confidence
Mentioned
$RGEN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENBearishMed
01

Why it matters

The sale reduces insider ownership, potentially influencing investor perception.

02

Market read

Insider sale may trigger short-term price decline; traders may consider adjusting positions.

03

What to watch

CEO may be diversifying portfolio; no immediate operational concerns disclosed.

Relevance 5/10Novelty 6/10Timing: post-market 2026-09-24

Background

Form 4 filing reports insider transactions; investors monitor for signals.

Company-level read

Ticker impact

$RGENBearishHigh confidence
Context

CEO Loeillot Olivier sold 12,946 shares for $2.46M via a 10b5-1 plan, reducing his stake to 48,369 shares.

Expected impact

Short-term downward pressure expected.

Evidence & confidence

Insider sale by CEO indicates possible lack of confidence; size relative to holdings is material.

Market effects

Sector

May affect biotech/healthcare sector sentiment as insider sales can be viewed broadly.

Regional

US market focus; limited regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

Sale could be routine 10b5-1 execution, not a bearish signal.

Key entities

  • Officer
    Loeillot Olivier

    Chief Executive Officer of Repligen Corp.

  • Company
    Repligen Corp

    Biopharmaceutical company listed on NASDAQ.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RGEN insider trading history →

Related articles

OCT 6
$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

SEC EDGAR 8-K2 min
OCT 6
$BLFSHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

SEC EDGAR 8-K2 min
OCT 6
$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

globenewswire.com1 min
OCT 5
$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.

securities.io3 min